rq3013
VaccineexperimentalCOVID-19
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2022 (NCT05396573)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05907044 | N/A | May 8, 2023 | Kunming Medical University, Yunnan University of Traditional Chinese Medicine |
| NCT05394012 | Phase 1 | Dec 31, 2022 | Shanghai RNACure Biopharma Co., Ltd., Walvax Biotechnology Co., Ltd. |
| NCT05396573 | Phase 1 | Jul 31, 2022 | Shanghai RNACure Biopharma Co., Ltd., Walvax Biotechnology Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai RNACure Biopharma Co., Ltd. | For profit | 2 | 0 | 1 | 2022 |
| Walvax Biotechnology Co., Ltd. | For profit | 2 | 2 | 1 | 2022 |
| Kunming Medical University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Yunnan University of Traditional Chinese Medicine | Academic/Hospital | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1